摘要
目的探讨DC-CIK细胞联合康莱特注射液治疗对晚期非小细胞肺癌患者免疫功能及生活质量的影响。方法将50例晚期非小细胞肺癌患者随机分为2组,对照组22例给予单纯对症支持治疗,治疗组28例在对照组治疗基础上给予DC-CIK细胞联合康莱特注射液治疗。采用流式细胞术检测外周血T淋巴细胞亚群的数量和比例,采用RECIST实体瘤疗效评价标准评估治疗效果,采用Karnofsky评分标准和体质量评价评估生存质量改善情况。结果对照组治疗前后外周血T淋巴细胞亚群CD3^+、CD4^+、CD8^+、CD4^+/CD8^+和CD4^+CD25^+Treg比较差异均无统计学意义(P均>0.05);治疗组治疗后外周血T淋巴细胞CD3^+、CD4^+及CD4^+CD25^+Treg均较治疗前及对照组明显改善(P均<0.05),CD4^+/CD8^+、CD8^+与治疗前及对照组比较差异无统计学意义(P均>0.05)。2组治疗有效率及疾病控制率比较差异均无统计学意义(P均>0.05)。治疗组KPS评分、体质量改善情况均明显优于对照组(P均<0.05)。治疗组中有10例出现发热症状,对症处理后恢复正常,无其他不良反应。结论 DC-CIK细胞联合康莱特注射液治疗能够明显改善晚期非小细胞肺癌患者的免疫功能及生存质量。
Objective It is to investigate the influence of DC- CIK cells combined with Kanglaite injection on immune function and quality of life of patients with advanced non-small-cell lung cancer（ NSCLC）. Methods A total of 50 patients with advanced NSCLC were randomly divided into 2 groups,22 cases in the control group were received only appropriate supportive care,and 28 cases in the treatment group were treated by DC- CIK cells combined with Kanglaite injection plus supportive care. The percentage and absolute number of peripheral blood T lymphocyte subsets were evaluated by flow cytometry.The clinical responses were evaluated using the Response Evaluation Criteria in Solid Tumors（ RECIST）. The performance status was measured by the Karnofsky Performance Status（ KPS） scale and body mass change. Results In the treatment group,the levels of CD3~＋,CD4~＋T lymphocyte subsets in peripheral blood were significantly increased（ all P 〈 0. 05） and CD4~＋CD25~＋Treg subset were significantly lower（ P 〈 0. 05） after treatment,while the level of CD8~＋subset and CD4~＋/CD8~＋ratio were stable. There was no significant alteration for these parameters in the control group. There was no significant differenct in the response rate and disease control rate between the both groups（ all P 〉 0. 05）. Compared with the control group,the KPS score and body mass change were significantly improved following the treatment of DC- CIK cells combined with Kanglaite injection（ all P 〈 0. 05）. Fever was observed in 10 patients in the treatment group,and the symptom was rapidly improved with supportive treatment. There was no other side effect in the treatment group. Conclusion DC- CIK cells combined with Kanglaite injection can improve immune function and quality of life in patients with advanced NSCLC.
出处
《现代中西医结合杂志》
CAS
2015年第36期4000-4002,4009,共4页
Modern Journal of Integrated Traditional Chinese and Western Medicine
基金
河北省中医药管理局资助项目(2013031)
